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Abstract: Lasofoxifene is a selective estrogen receptor modulator (estrogen agonist/antagonist) 
that has completed phase III trials to evaluate safety and efficacy for the prevention and 
treatment of osteoporosis and for the treatment of vaginal atrophy in postmenopausal women. 
In postmenopausal women with low or normal bone mineral density (BMD), lasofoxifene 
increased BMD at the lumbar spine and hip and reduced bone turnover markers compared with 
placebo. In women with postmenopausal osteoporosis, lasofoxifene increased BMD, reduced 
bone turnover markers, reduced the risk of vertebral and nonvertebral fractures, and decreased 
the risk of estrogen receptor-positive breast cancer. In postmenopausal women with low bone 
mass, lasofoxifene improved the signs and symptoms of vulvovaginal atrophy. Clinical trials show 
that lasofoxifene is generally well tolerated with mild to moderate adverse events that commonly 
resolve even with drug continuation. Lasofoxifene has been associated with an increase in the 
incidence of venous thromboembolic events, hot flushes, muscle spasm, and vaginal bleeding. 
It is approved for the treatment of postmenopausal women at increased risk for fracture in some 
countries and is in the regulatory review process in others.
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Introduction
Osteoporosis is a systemic skeletal disease characterized by low bone mineral density 
(BMD) and poor bone quality that reduces bone strength and increases the risk of 
fractures.1 It is a major public health concern with serious clinical and economic 
consequences.2,3 Osteoporosis affects about 200 million people worldwide, including 
one-third of women between the ages of 60 and 70 years, and two-thirds of women 
aged 80 years and older,4 with 30% of women over the age of 50 years having one or 
more vertebral fractures.5 Fractures of the spine and hip are associated with increased 
morbidity and mortality.6,7 The direct health care cost in the United States (US) for 
fracture-related medical care was about US$17 billion in 20058 and over  36 million 
in Europe in 2000.9
Osteoporosis is diagnosed with BMD testing by dual-energy X-ray absorptiometry 
(DXA) according to criteria established by the World Health Organization10 (WHO) 
as adapted for use in clinical practice by the International Society for Clinical 
Densitometry11 (ISCD). Guidelines for the initiation of a pharmacological agent to 
reduce fracture risk are commonly based on estimation of fracture risk according 
to BMD T-score and/or clinical risk factors (CRFs) for fracture. Recent efforts to 
better identify patients at high risk for fracture have combined BMD with CRFs for 
fracture, which predicts fracture risk better than BMD or CRFs alone.3,12,13 The WHO Therapeutics and Clinical Risk Management 2009:5 818
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fracture risk assessment algorithm14 (FRAX) uses validated 
CRFs and femoral neck BMD, if available, to estimate the 
10-year probability of major osteoporotic fracture (spine, 
hip, proximal humerus, and distal forearm) and the 10-year 
probability of hip fracture. Cost-effective country-specific 
intervention thresholds have been developed using FRAX 
with epidemiological data and numerous economic assump-
tions (eg, economic resources, health care priorities, societal 
willingness to pay).15,16 Patients who have the highest risk 
for fracture have the greatest fracture risk reduction with 
drug therapy.17,18 However, despite the availability of safe 
cost-effective drugs to reduce fracture risk, challenges 
remain. Osteoporosis continues to be underdiagnosed19,20 
and undertreated,21,22 even in patients at very high risk of 
fracture.23,24 When treatment is prescribed, some patients do 
not fill the prescription and many do not take it correctly or 
long enough to benefit.25
Pharmacological agents proven to reduce fracture risk 
include estrogen with or without medroxyprogesterone,26,27 
alendronate,28–30 risedronate,31–33 ibandronate,34 zoledronate,35,36 
salmon calcitonin,37 strontium ranelate,38,39 raloxifene,40 
bazedoxifene,41 lasofoxifene,42 teriparatide,43 and recombi-
nant human parathyroid hormone (1–84).44
Oral bisphosphonates (eg, alendronate, risedronate, 
ibandronate) are generally considered to be first line therapy 
for osteoporosis because of their proven efficacy in reducing 
fracture risk and good safety profile. However, oral dosing 
of bisphosphonates is complex (pre-dose fasting, ingestion 
with plain water only, post-dose fasting in upright position) 
and has been associated with gastrointestinal (GI) adverse 
events in clinical practice patients.45 Intermittent intravenous 
(IV) bisphosphonates (eg, ibandronate, zoledronate) do not 
have GI intolerance concerns, but must be given by office 
staff trained in their administration or at an infusion center. 
The selective estrogen receptor modulator (SERM) drug 
class (eg, tamoxifen, clomiphene, raloxifene, bazedoxifene, 
arzoxifene, lasofoxifene) has been reclassified by the US 
Food and Drug Administration (FDA) as “estrogen agonist/
antagonists.” These drugs, as with other antiresorptive agents, 
improve bone strength and reduce fracture risk by decreasing 
bone turnover, resulting in stabilization or an increase in 
BMD, preservation of bone microarchitecture, reduction in 
trabecular perforation, and a decrease in cortical porosity. 
The BMD increases that are observed with reduced bone 
turnover are due to filling in of the remodeling space and 
increased secondary mineralization.
The SERMs are a heterogeneous group of compounds 
that attach to the ligand-binding domain of estrogen receptors 
alpha (ERα) and beta (ERβ) through their stilbene-like 
cores. The resulting conformational changes at the ligand-
binding domain may differ from estrogen depending on the 
physiochemical properties of the SERM. The estrogen-agonist 
or estrogen-antagonist effects of SERMs vary according to 
the expression of co-activators and/or co-repressors of gene 
activity in the target cell or tissue type. Tamoxifen is a SERM 
that inhibits the proliferation of breast cancer cells,46 but its 
use is limited due to undesirable effects on the endometrium.47 
It is approved for prevention and treatment of postmenopausal 
estrogen receptor-positive (ER+) breast cancer. Another 
SERM, clomiphene, is approved for infertility treatment in 
premenopausal women. Raloxifene is approved for prevention 
and treatment of postmenopausal osteoporosis (PMO), 
reduction in risk of invasive breast cancer in postmenopausal 
women with osteoporosis, and prevention of breast cancer 
in high-risk postmenopausal women. It has desirable 
estrogen-like effects on the skeleton, with antiresorptive 
activity resulting in stabilization or improvement in BMD 
and reduction in the risk of vertebral fractures.40 It also 
has beneficial antiestrogen effects in breast tissue, where it 
has been shown to reduce the risk of invasive breast cancer 
similar to tamoxifen.48 Undesirable effects include increased 
risk of thromboembolic events and hot flushes.40 An ideal 
SERM for the management of PMO would reduce bone 
remodeling, stabilize or increase BMD, and decrease fracture 
risk throughout the skeleton, while mitigating or eliminating 
menopausal symptoms (eg, hot flushes, vaginal dryness) and 
having neutral or beneficial effects on breast and endometrial 
cells, lipids, cardiovascular and thromboembolic disease, 
cognitive function, and urogenital function. Systematic 
screening of candidate compounds has been conducted to 
search for those with optimal therapeutic profiles. Some 
molecules (eg, droloxifene, levormeloxifene, idoxifene) 
that initially appeared promising subsequently failed due 
to adverse effects, primarily with the uterus.49 In a pivotal, 
five-year, phase III trial, arzoxifene was reported to decrease 
the risk of vertebral fractures and invasive breast cancer in 
postmenopausal women with osteoporosis, but was dropped 
from clinical development due to failure to demonstrate a 
statistically significant difference in key secondary efficacy 
endpoints, such as nonvertebral fractures, clinical vertebral 
fractures, cardiovascular events, and cognitive function, 
compared to placebo.50 Bazedoxifene, which has been shown 
to reduce the risk of vertebral fractures in postmenopausal 
women with osteoporosis,41 is approved for use in the 
European Union (EU) and is under regulatory review in the 
US (Table 1).Therapeutics and Clinical Risk Management 2009:5 819
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This is a review of the data evaluating lasofoxifene tartrate 
(CP-336,156, CP-336156, Fablyn, formerly Oporia, Pfizer 
Inc. and Ligand Pharmaceuticals) for use in the prevention 
and treatment of PMO.
Structure and mechanism of action
SERMs may be classified according to their core structure, 
which is typically a variation of the 17β-estradiol template, 
and sub-classified according to the side-chain at the helix 
12 affector region.51 The triphenylethylenes have a stilbene 
core that mimics the nonsteroidal agonist diethylstilbestrol. 
Tamoxifen, a drug used in the management of breast cancer, 
is perhaps the best known of the triphenylethylenes; others 
include clomiphene, toremifene, droloxifene, miproxifene, 
and idoxifene. The clinical applications of this class of 
SERMs have often been limited due to adverse effects 
on the uterus. The benzothiophenes, such as raloxifene 
and arzoxifene, are associated with skeletal benefit while 
having little if any uterine stimulation. Indole-based SERMs 
(eg, zindoxifene, pipindoxifene, and bazedoxifene) have 
a 2-phenyl ring system that serves as a core binding unit.52 
Other classes are the benzopyrans (eg, levormeloxifene) and 
the napthalenes (eg, nafoxidene, trioxifene, lasofoxifene).
Lasofoxifene [(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-
5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthalenol] 
(Figure 1) was developed through a systematic drug 
discovery program intended to find a nonsteroidal agent 
with properties of good oral bioavailability and the beneficial 
effects of estrogen.53 Structural classes known to interact 
with the estrogen receptor, including the benzothiophenes, 
were surveyed. Since there was evidence that extensive 
gastrointestinal (GI) glucuronidation of the 6- and 4’-hydroxyl 
groups of orally administered raloxifene was responsible 
for its limited systemic bioavailability and reduced potency 
compared with estrogen, the search was directed toward 
modifying the benzothiophene to reduce glucuronidation. 
Experiments ultimately resulted in the discovery of 
CP-336,156 (later called lasofoxifene), a SERM with excellent 
oral bioavailability due to minimal GI glucuronidation, and 
potency similar to estrogen at preventing bone loss and 
lowering total serum cholesterol in rats, without estrogen-
like proliferative effects on breast and uterine tissue. This 
provided the basis for its clinical development as a potential 
agent in the management of PMO.
Lasofoxifene has a high affinity for both ERα and ERβ, 
approximately the same as estradiol, and about 10-fold 
higher than SERMs such as raloxifene, tamoxifen, and 
droloxifene.54,55 Lasofoxifene is also highly selective, 
having more than a 100-fold selectivity against all other 
steroid receptors.53,56 The high bioavailability of lasofoxifene 
(about 60%) may contribute to the observed high potency 
(as assessed by alteration of estrogen-sensitive biomarkers) 
reported in early animal53 and human studies.57
Pharmacological properties
A 14-day, randomized, placebo-controlled, investigator blind, 
multiple dose study of the clinical pharmacology of lasofoxi-
fene was conducted in 65 healthy postmenopausal women 
(age range 48–61 years).57 Lasofoxifene was administered 
under supervision after an overnight fast of at least eight hours 
as an oral solution, with a loading dose of five times the daily 
dose followed by daily doses of 0.01 mg, 0.03 mg, 0.1 mg, 
0.3 mg, 1 mg, or placebo. A loading dose was used in order 
to shorten the time required to achieve steady-state plasma 
concentrations. Samples were collected for pharmacokinetic 
and pharmacodynamic assessments. Peak plasma concentra-
tions (Cmax) were reached in about 6.0 to 7.3 hours, compared 
with a shorter Cmax of 0.5 hours that has been reported with 
raloxifene.58 The mean half-life was 165 hours (∼six days) 
with a range of 96–222 hours and mean maximum plasma 
Table 1 Key efficacy and safety endpoints of lasofoxifene compared with bazedoxifene and raloxifene in postmenopausal women with 
osteoporosis
Efficacy Safety Regulatory 
Status
Lasofoxifene Decreased risk of vertebral fractures 
and nonvertebral fractures; reduced 
risk of breast cancer; relieved 
symptoms of vulvovaginal atrophy
increased risk of vTe; increased risk of vaginal 
bleeding
Approved in eU
Bazedoxifene Decreased risk of vertebral fractures increased risk of vTe Approved in eU
Raloxifene Decreased risk of vertebral fractures; 
reduced risk of breast cancer
increased risk of vTe; increased risk of fatal 
stroke in postmenopausal women at high risk 
for coronary artery disease
Approved in US, eU, 
and other countries
Abbreviations: eU, european Union;    vTe, venous thromboembolic events;  US, United States.Therapeutics and Clinical Risk Management 2009:5 820
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concentration ranging from 0.09 ng/mL to 6.43 ng/mL. This 
compares with a far shorter mean half-life of about 32.5 hours 
(range 15.9–86.6 hours) with raloxifene,59 but is similar to 
the reported half-lives of other SERMs, such as toremifene 
and tamoxifen.58 Administration of loading doses resulted in 
reaching steady-state concentrations within approximately 
seven to nine days. The pharmacokinetics of lasofoxifene are 
linear over a wide dose-range (0.01 to 100 mg)57 and are not 
significantly affected by age, ethnicity, weight, moderately 
impaired hepatic or renal function, or medications such 
as warfarin, ketoconazole, and digoxin.60–63 In a study of 
lasofoxifene disposition in healthy male subjects, it was 
eliminated by phase I oxidative metabolism (largely mediated 
by CYP2D6 and CYP3A4) and phase II conjugation.64
Preclinical studies
Lasofoxifene was identified as a SERM with potential 
clinical utility through a systematic drug discovery program 
for screening candidate compounds in three stages: 
1) measurement of the half-maximal inhibitory concentration 
(IC50) for estradiol binding to the estrogen receptor in the rat, 
2) efficacy in the prevention of bone loss in ovariectomized 
(OVX) rats, and 3) antiproliferative effects in the estrogen 
sensitive MCF-7 breast cancer cell line.53 Particular attention 
was paid to oral bioavailability of these compounds, which 
was improved with greater resistance to intestinal wall gluc-
uronidation. Lasofoxifene ultimately emerged as the SERM 
with the most favorable overall profile for pharmacokinetics 
and efficacy. An extensive preclinical program for further 
study of lasofoxifene was then initiated.
In five-month old OVX Sprague-Dawley rats, lasofoxi-
fene prevented bone loss, inhibited bone turnover, and 
prevented OVX-induced increases in body weight and total 
cholesterol.56 In a study of immature (three weeks old) female 
Sprague–Dawley rats, lasofoxifene had no effect on uterine 
wet or dry weight, and in aged (17 months old) female rats no 
uterine hypertrophy was observed.56 In the aged female rats, 
there was a decrease in total serum cholesterol, a decrease 
in fat body mass, and no effect on lean body mass. Bone 
histomorphometry parameters with lasofoxifene-treated 
OVX rats were fully equivalent with what was observed 
in those treated with estradiol.56 In 10-month-old male 
Sprague–Dawley rats, 60 days of treatment with lasofoxifene 
prevented bone loss induced by aging and orchidectomy, 
reduced bone turnover, and decreased serum cholesterol, 
with no effect on the prostate.65 Long-term (60 days) of 
treatment with lasofoxifene in aged (15-month-old) male 
rats prevented age-related decreases in bone mass and bone 
strength by inhibiting bone turnover, with a decrease in serum 
cholesterol and no change in prostate weight.66 In a two-year 
study of OVX female cynomolgus monkeys (Macaca fas-
cicularis), lasofoxifene prevented OVX-induced loss of bone 
and rise in bone turnover,67 did not increase uterine weight 
or endometrial thickness, and did not change the histology 
of mammary, vaginal, or cervical tissue.68 Mild endometrial 
fibrosis and cystic changes were seen in the lasofoxifene-
treated animals, while significant increases in uterine weight 
and endometrial hyperplasia were found in those treated with 
conjugated equine estrogen.
Efficacy in clinical studies
Sources of information on the clinical use of lasofoxifene 
were abstracts presented at scientific meetings, a few publi-
cations in peer reviewed scientific journals, and documents 
prepared for regulatory review.69,70
In a 14-day phase I study of variable doses of lasofoxi-
fene in healthy postmenopausal women, lasofoxifene was 
associated with partial suppression of luteinizing hormone, 
follicle-stimulating hormone, and low-density lipoprotein 
(LDL) cholesterol.57 Urinary N-telopeptide (NTX) tended to 
decrease with an increase in the lasofoxifene dose, with the 
greatest decrease in NTX observed with the highest (0.3 mg 
Figure 1 Lasofoxifene.
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and 1.0 mg/day) doses. There were no significant reported 
decreases in serum bone-specific alkaline phosphatase 
(BSAP) with 14 days of lasofoxifene treatment.
A two-year phase II randomized, double-blind, active 
treatment and placebo controlled clinical trial compared the 
effects of two doses of lasofoxifene (0.25 mg and 1.0 mg/day) 
with raloxifene 60 mg/day and placebo in 410 postmenopausal 
women with baseline lumbar spine Z-scores between +2.0 
and -2.5.71 This range of BMD was selected in order to 
evaluate the response of lasofoxifene for both the prevention 
and treatment of PMO. The primary efficacy endpoint was 
the percentage change in lumbar spine (L1–L4) BMD at 
two years compared with baseline. Secondary endpoints 
included the percentage change in bone turnover markers 
at two years compared with baseline, and changes in serum 
markers of lipid metabolism, coagulation, and inflammation 
at various time points during the study. At two years there was 
a significant increase in lumbar spine BMD with both doses 
of lasofoxifene compared with baseline (1.8% and 2.2% for 
0.25 mg and 1.0 mg/day, respectively, P  0.05), compared 
with raloxifene (1.9% and 2.3% for 0.25 mg and 1.0 mg/day, 
respectively, P  0.05), and compared to placebo (3.6%% and 
3.9% for 0.25 mg and 1.0 mg/day, respectively, P  0.05). 
Both drugs were equally effective at increasing total hip BMD 
and both drugs reduced bone turnover marker levels, with 
the effects of lasofoxifene generally greater than raloxifene. 
There was a significant reduction in LDL cholesterol levels at 
two years with lasofoxifene (20.6% and 19.7% with 0.25 mg 
and 1.0 mg/day, respectively, P  0.05) compared with 
raloxifene (12.1% decrease) and placebo (3.2% decrease). 
Lasofoxifene resulted in significantly greater decreases in 
total serum cholesterol and apolipoprotein (Apo) B-100, 
and a significantly greater increase in Apo A-1, compared 
with raloxifene, while there were no significant changes in 
high-density lipoprotein (HDL) cholesterol or triglycerides 
in any group. Both lasofoxifene and raloxifene reduced 
levels of fibrinogen and antithrombin III compared with 
placebo, with the reduction greater with lasofoxifene than 
with raloxifene.
The Postmenopausal Evaluation And Risk-reduction with 
Lasofoxifene (PEARL) study was a five-year (with three-
year analysis) randomized double-blind, placebo-controlled, 
phase III clinical trial (A2181002) evaluating the efficacy 
and safety of lasofoxifene in women with PMO.42,72 The 
primary outcome measures were new morphometric vertebral 
fractures at three years, new cases of ER+ breast cancer at 
five years, and new nonvertebral fractures at five years. 
Secondary outcome measures included, clinical vertebral 
and multiple vertebral fractures, all clinical fractures, 
nonvertebral fractures, hip fractures, BMD, breast cancer, 
cardiovascular events, and gynecological safety events at 
three years, and all clinical fractures, new morphometric 
vertebral fractures, BMD, cardiovascular events, and gyne-
cological safety events at five years. A total of 8,556 women 
aged 59–80 years with lumbar spine or femoral neck 
T-score -2.5 or less was enrolled. Women with a baseline 
T-score  -4.5 at either skeletal site, or more than three 
morphometric vertebral fractures, or a vertebral fracture in 
the past year were excluded. Participants received calcium 
1,000 mg and vitamin D 400–800 IU per day. Study subjects 
were randomized to receive lasofoxifene 0.25 mg or 0.5 mg/d 
or placebo. Compared with placebo, three years of lasofoxi-
fene increased lumbar spine BMD by 3.3% (both doses, 
P  0.001), and increased femoral neck BMD by 2.7% and 
3.3% with 0.25 mg and 0.5 mg/d, respectively (P  0.001). 
Over three years, lasofoxifene 0.25 mg and 0.5 mg/d reduced 
the risk of vertebral fractures by 31% and 42%, respectively 
(P  0.002), while nonvertebral fractures were significantly 
reduced by 22% with the 0.5 mg/d dose (P = 0.02) but not 
with the 0.25 mg/d dose (14% decrease, P = 0.13) (Figure 2). 
Both doses of lasofoxifene resulted in a significant reduction 
in bone turnover markers compared with placebo, with the 
median marker levels in the lower half of the premenopausal 
reference range.
PEARL was the only lasofoxifene study to evaluate breast 
cancer risk as an efficacy endpoint. It was found that both 
lasofoxifene 0.25 mg and 0.5 mg significantly reduced the 
risk of ER+ breast cancer through three years (84% reduction 
with lasofoxifene 0.25 mg and 67% reduction with lasofoxi-
fene 0.5 mg), with only lasofoxifene 0.5 mg significantly 
reducing the risk of ER+ breast cancer (by 81%) through five 
years compared with placebo. Both lasofoxifene 0.25 mg and 
0.5 mg significantly reduced the risk of ER+ invasive breast 
cancer through three years (82% reduction with lasofoxi-
fene 0.25 mg and 73% reduction with lasofoxifene 0.5 mg). 
Lasofoxifene 0.5 mg significantly reduced the risk of ER+ 
invasive breast cancer by 83% through five years.
The Osteoporosis Prevention And Lipid lowering (OPAL) 
study consisted of two identical two-year double-blind, 
placebo-controlled, phase III clinical trials (A2181003 and 
A2181004) that evaluated the efficacy and safety of three 
doses of lasofoxifene (0.025 mg, 0.25 mg, and 0.5 mg/d) 
or placebo. A total of 1,907 postmenopausal women aged 
40–75 years with normal or low BMD (lumbar spine 
T-score 0.0 and -2.5) were enrolled.73,74 The primary 
efficacy endpoints were change in lumbar spine (L1–L4) Therapeutics and Clinical Risk Management 2009:5 822
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BMD by DXA from baseline at 24 months and in serum 
LDL cholesterol at six months. Secondary efficacy end 
points included hip BMD by DXA at six, 12, and 24 months, 
lumbar spine (L1–L4) BMD at six and 12 months, and change 
from baseline at six and 24 months in serum concentrations 
of bone turnover markers: resorption marker C-terminal 
telopeptide of type 1 collagen (CTX) and formation mark-
ers osteocalcin (OC) and procollagen type 1 N-terminal 
peptide (P1NP). Other endpoints included BMD at the hip 
and effects on extraskeletal tissue such as breast, vagina, 
brain, and cardiovascular system. All patients received 1000 
mg calcium and 200 to 500 IU vitamin D daily. Pooled 
results from the 2 OPAL trials have been presented as 
abstracts.73,74 Lumbar spine BMD increases from baseline 
in all lasofoxifene-treated groups were statistically supe-
rior to placebo (P  0.0001) at the first time point tested 
(six months) and were sustained throughout the 24-month 
study. Subjects in the 0.25 and 0.5 mg/d lasofoxifene groups 
experienced equivalent changes from baseline (2.3% increase 
for both doses at two years, P  0.001) in lumbar spine BMD, 
compared with a 0.7% decrease with placebo; these changes 
were statistically superior (P = 0.0002) to those experienced 
by the 0.025 mg/d group at six, 12, and 24 months. The pat-
tern of hip BMD change was similar to lumbar spine BMD, 
with all groups receiving lasofoxifene superior to placebo 
(P  0.001) at the earliest time point tested (six months) 
and remaining superior through 24 months. Subjects in the 
0.25 and 0.5 mg/d lasofoxifene groups experienced similar 
changes from baseline in hip BMD; these changes were 
statistically superior (P  0.05) to those of the 0.025 mg/d 
group at six, 12, and 24 months. Lasofoxifene at all doses 
significantly (P  0.001) decreased median serum levels of 
CTX relative to placebo at six months, indicating a reduced 
rate of bone resorption. Compared to placebo, serum CTX 
was 50% lower with lasofoxifene 0.25 mg/d and 51% lower 
with lasofoxifene 0.5 mg/d. At 24 months, median CTX levels 
were reduced from baseline in the 0.025 mg, 0.25 mg, and 
0.5 mg/d dose groups by 0.0%, 12%, and 17%, respectively, 
compared with a 34% increase in placebo-treated subjects. 
The 0.25 mg and 0.5 mg/d lasofoxifene doses produced 
similar effects on CTX, and both doses were statistically 
superior (P = 0.001) in suppressing CTX compared with 
0.025 mg/d. Lasofoxifene at all doses produced significant 
reductions in serum OC at six months, relative to placebo 
(P  0.001). Compared to placebo, serum OC was 29% lower 
with lasofoxifene 0.25 mg/d. At 24 months, median OC levels 
decreased by 9%, 20%, and 17% for lasofoxifene, compared 
with an increase of 7% for placebo. The 0.25 mg and 0.5 mg/d 
lasofoxifene treatment groups produced similar changes in 
OC, and both doses were statistically superior (P  0.001) to 
0.025 mg/d. Lasofoxifene at all doses significantly decreased 
median levels of P1NP relative to placebo at six months 
(P  0.001). Compared to placebo, serum P1NP was 35% 
lower with lasofoxifene 0.25 mg/d. At 24 months, levels of 
P1NP were reduced by 22%, 33% and 33% in the 0.025 mg/d, 
0.25 mg/d, and 0.5 mg/d lasofoxifene dose groups, respectively, 
compared to an increase of 3% in placebo-treated patients. 
P1NP reductions with lasofoxifene 0.25 mg/d and 0.5 mg/d 
were similar. Changes in signs and self-assessed symptoms 
of vaginal atrophy, cognitive function, and lipids were 
periodically analyzed over 24 months. No increase in breast 
density or breast pain was reported in the lasofoxifene groups. 
Figure 2 Three-year fracture risk in postmenopausal women treated with lasofoxifene.69 There was a statistically significant reduction in the risk of vertebral fractures with 
lasofoxifene 0.25 mg and 0.5 mg/d and a statistically significant reduction in the risk of nonvertebral fractures (defined as all fractures except fingers, toes, face, and skull) with 
lasofoxifene 0.5 mg/d.
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Vaginal pH and the maturation index were improved at 
12 and 24 months in all 3 lasofoxifene groups. At 24 months, 
lasofoxifene subjects had significantly lower percentages 
of parabasal cells and significantly higher percentages of 
immediate cells and superficial cells in the vagina versus 
PBO (P = 0.004). There was a significant improvement in 
vaginal pH at 12 and 24 months for all doses of lasofoxi-
fene compared with placebo (P  0.001). At 12 months, 
all lasofoxifene doses significantly decreased median LDL 
cholesterol, total cholesterol (TC), TC/HDL-cholesterol 
ratio, Apo B100, Apo B-100/Apo A1 ratio, high sensitivity 
C-reactive protein (CRP) and lipoprotein (a) versus placebo. 
There was a beneficial effect on Apo A1, a small decrease 
in HDL-cholesterol in one lasofoxifene group, and a 0.5 to 
7.3% increase in median triglyceride levels. At 24 months, 
fibrinogen levels significantly decreased from baseline for 
all lasofoxifene groups compared with placebo.
A two-year randomized, double-blind, placebo-controlled 
trial  evaluated  bone  turnover  marker  changes  in 
51 postmenopausal women with osteopenia receiving either 
lasofoxifene 0.25 mg/d or placebo.75 It was found that 
decreases in serum P1NP and urinary NTX at six months 
predicted an increase in lumbar spine and total hip BMD 
at one and two years, with almost all lasofoxifene-treated 
women (92% to 96%) having a significant decrease in 
serum-based bone turnover markers. This suggests that bone 
turnover markers may be useful in the early monitoring of 
patients treated with lasofoxifene and predictive of a subse-
quent BMD response.
Comparison of Raloxifene and Lasofoxifene (CORAL) 
was a two-year randomized, double-blind, placebo- and active 
treatment-controlled, parallel group phase III clinical trial 
(A2181030) in women aged 48–75 years who were least three 
years postmenopausal with a lumbar spine T-score  -2.5 
and 0.0. Subjects were randomized to receive lasofoxifene 
0.25 mg/d, raloxifene 60 mg/d, or placebo. The primary 
endpoints were percentage change in lumbar spine BMD 
at 24 months compared with baseline and the percentage of 
BMD responders at 24 months. The results of CORAL have 
not been released.
Two pivotal, 12-week, phase III trials (A2181031 and 
A2181032) of identical design evaluated the efficacy of 
lasofoxifene 0.25 mg and 0.5 mg versus placebo in treatment 
of moderate to severe symptoms of vulvovaginal atrophy in 
postmenopausal women with low bone mass.69 There were 
four co-primary endpoints (measured as a change from 
baseline to week 12): subject self-assessed most bothersome 
moderate or severe baseline vulvovaginal symptom, vaginal 
pH, percentage of vaginal parabasal cells, and percentage of 
vaginal superficial cells. The findings were consistent with a 
beneficial effect of lasofoxifene on the signs and symptoms 
of postmenopausal vulvovaginal atrophy, and similar to what 
was reported in the PEARL study.
Safety and tolerability
Preclinical toxicology studies with lasofoxifene did not 
identify significant safety issues with regard to the intended 
use of lasofoxifene in postmenopausal women.69 In 23 clinical 
pharmacology studies in which most patients received a 
single dose of lasofoxifene, adverse events were mild, with 
no deaths or serious adverse events reported.69 A phase I 
study of lasofoxifene in healthy postmenopausal women 
reported a total of 62 adverse events in 23 of the 49 subjects 
treated with lasofoxifene, 31 of which were considered to be 
treatment-associated.57 The most frequently reported adverse 
events with lasofoxifene were headache, dizziness, nausea, 
hot flushes, and diarrhea. A total of eight adverse events was 
reported by five of 16 subjects receiving placebo, with the 
most frequently reported being headache and malaise. All of 
the adverse events associated with treatment were mild, and 
almost all adverse events resolved within 24 hours. There 
were no severe adverse events and no withdrawals due to 
adverse events reported during the study. Clinical labora-
tory abnormalities were generally transient and appeared 
unrelated to the study drug. The most common abnormali-
ties, many of which were associated with abnormal baseline 
levels, included elevations in triglycerides, total cholesterol, 
and urine white blood cells.
Safety data from 17 phase II and III clinical trials, 
reported in a briefing document prepared for the FDA,69 
included assessment of adverse events, serious adverse 
events, premature discontinuation, laboratory test abnormali-
ties, vital signs, electrocardiogram parameters, and analyses 
of gynecological and cardiovascular safety. The adverse 
event profile was generally consistent with that seen for 
other SERMs. Reports from the phase II and III clinical 
program showed comparable rates of adverse events among 
treatment groups (89% in the placebo, 92% in the 0.25 mg, 
92% in the lasofoxifene 0.5 mg/d groups, and 92% for the 
pooled doses group, respectively), with most adverse events 
mild or moderate in intensity. The most commonly reported 
adverse events that appeared to be associated with lasofoxi-
fene 0.5 mg/d treatment were hot flush, muscle spasms, and 
vaginal discharge. Hot flush was reported for 7% of patients 
who received placebo compared with 15% who received 
lasofoxifene 0.5 mg. Muscle spasms were reported for Therapeutics and Clinical Risk Management 2009:5 824
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8% of patients who received placebo compared with 16% 
of patients who received lasofoxifene 0.5 mg/d. Vaginal 
discharge was reported for 3% of patients who received 
placebo compared to 6% of those who received lasofoxifene 
0.5 mg, with significant improvement in symptoms of 
postmenopausal vulvovaginal atrophy in association with 
decreased vaginal pH, increased vaginal lubrication, and 
improved vaginal cell maturation index. Discontinuation 
of study treatment due to an adverse event occurred in 
443 (9.4%), 515 (11.3%), 464 (10.8%), 1132 (11.0%) patients 
in the placebo, lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, 
and pooled lasofoxifene treatment groups, respectively. The 
most frequent causes of discontinuation from lasofoxifene 
treatment were hot flushes, muscle spasm, and deep vein 
thrombosis. All causality serious adverse events were reported 
in 876 (18.6%), 962 (21.1%), 888 (20.6%), and 1926 (18.8%) 
patients in the placebo, lasofoxifene 0.25 mg/d, lasofoxifene 
0.5 mg/d, and pooled lasofoxifene groups, respectively. Falls, 
cholelithiasis, osteoarthritis, cataracts, and pneumonia were 
the most common serious adverse events in patients treated 
with lasofoxifene or placebo; the incidence of these events 
was similar across treatment groups. There was a slightly 
increased all-cause mortality observed in the five-year 
PEARL data for those on lasofoxifene 0.25 mg/d (hazard 
ratio [HR] 1.38, P = 0.0489) compared with placebo, but no 
significant increase in mortality in the lasofoxifene 0.5 mg/d 
group or the pooled data for both 0.25 and 0.5 mg/d. There 
was no dose response relationship with mortality and no 
pattern of causality; no plausible explanation has emerged 
to account for this observation, the clinical significance of 
which remains uncertain.
Safety endpoints of particular interest were identified 
by the FDA in the categories of venous thromboembolic 
events, stroke, other cardiovascular events, and gynecological 
adverse events.70 In the PEARL study, the preliminary 
five-year data showed a statistically significant increase in 
the risk of any venous thromboembolic event (HR 2.055, 
P = 0.011), deep vein thrombosis (HR 2.152, P = 0.020), 
and pulmonary embolism (HR 4.493, P = 0.035) with 
lasofoxifene 0.5 mg/d compared with placebo, while there was 
no significant increase in the risk of retinal vein thrombosis, 
total strokes, or fatal strokes.70 When transient ischemic 
events were excluded, lasofoxifene treatment with 0.25 mg 
and 0.5 mg/d was associated with a statistically significant 
decrease in the risk of strokes through five years (HR 0.61, 
P = 0.031 and HR 0.64, P = 0.043, respectively). Lasofoxifene 
treatment was not associated with an increase in the risk of 
fatal or nonfatal major coronary events and did not appear 
to have a significant effect on blood pressure or heart rate. 
Lasofoxifene 0.5 mg/d, but not 0.25 mg/d, was associated with 
a statistically significant decrease in major coronary events 
at five years (HR 0.68, P = 0.016). There was no significant 
increase in the risk of endometrial carcinoma in pooled data 
in 7,268 patients treated with lasofoxifene compared with 
3,291 on placebo. Two cases of uterine sarcoma were reported 
in lasofoxifene-treated patients, with a possibility that both 
may have been pre-existing prior to exposure to lasofoxifene. 
There was no evidence of a clinically significant increase in 
the incidence of endometrial hyperplasia with lasofoxifene, 
and no increase in uterine leiomyomata, pelvic prolapse, or 
urinary incontinence. In two subgroup analyses in the PEARL 
study, an approximately twofold increase in the incidence of 
histologically confirmed endometrial polyps was observed. 
Endometrial polyps are associated with vaginal bleeding, 
but have a low risk for developing malignant features (less 
than 2%). In a PEARL endometrial substudy, 17.9% of 
patients receiving lasofoxifene 0.5 mg/d were reported to 
have an increase in endometrial thickness (attributed to 
benign cystic atrophy, not hyperplasia) of at least 8 mm 
compared to none of the patients treated with placebo. The 
risk of vaginal bleeding was significantly increased in the 
pooled lasofoxifene groups in the PEARL study compared 
with placebo (HR 1.82, P = 0.0014), with the number of 
uterine-related procedures in lasofoxifene-treated patients 
who were not closely monitored about twofold greater than 
in those taking placebo.
Discussion
The SERM class of therapeutic agents occupies a unique 
niche in the management of PMO due to the broad range 
of nonskeletal as well as skeletal effects. While the ideal 
SERM (ie, one that enhances skeletal health while having 
neutral or beneficial effects on estrogen-sensitive nonskeletal 
tissue) has not yet been developed, lasofoxifene may provide 
an improved benefit-risk ratio compared with raloxifene. Its 
place amidst other drugs used to treat PMO, and its long-term 
(greater than five years) safety, are not yet known. It may 
have particular clinical utility in postmenopausal women 
who are at risk for nonvertebral fractures as well as vertebral 
fractures, especially those with symptoms of vulvovaginal 
atrophy or high risk for breast cancer.
The evidence from lasofoxifene clinical trials suggests 
that the 0.5 mg daily dose is the most efficacious for the 
treatment of postmenopausal women with osteoporosis. 
It was associated with a 42% reduction in the risk of new or 
worsening vertebral fractures and a 22% reduction in the risk Therapeutics and Clinical Risk Management 2009:5 825
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of nonvertebral fractures through three years, with sustained 
fracture risk reduction through five years. It increased BMD 
at the lumbar spine and hip, and reduced markers of bone 
turnover. Lasofoxifene 0.5 mg/d also reduced the risk of ER+ 
breast cancer by 67% through three years and 81% through 
five years; reduced the risk of ER+ invasive breast cancer 
by 73% through three years and 83% through five years; and 
reduced the risk of all breast cancers by 65% through three 
years and 79% through five years compared with placebo, and 
reduces symptoms associated with vulvovaginal atrophy.
The five-year PEARL safety data evaluated 5,701 women 
who received lasofoxifene for a total exposure of 23,058 
patient-years. Lasofoxifene was well tolerated, with a 
generally good safety profile and no evidence of increase 
risk of endometrial cancer. The overall incidence of adverse 
events, serious adverse events, and deaths was similar to 
placebo. As with estrogen and other SERMs, lasofoxifene 
increases the risk of venous thromboembolic events by about 
twofold. It did not increase risk of all strokes or fatal strokes 
and did not increase the risk of major coronary events. TC, 
LDL-cholesterol, and high sensitivity CRP levels were 
reduced at three years compared with placebo. Lasofoxifene 
did not increase the risk of endometrial cancer, endometrial 
hyperplasia, uterine prolapse, or urinary incontinence. 
Lasofoxifene was associated with an increase in endome-
trial thickness, benign endometrial polyps, and vaginal 
bleeding, requiring additional uterine procedures compared 
to placebo.
In August 2004, a new drug application (NDA) was filed 
with the FDA for lasofoxifene (as Oporia) 0.25 mg/d for the 
prevention of postmenopausal osteoporosis (NDA 21–757), 
followed by an additional filing for the treatment of vaginal 
atrophy in postmenopausal women with low bone mass (NDA 
21–843) in December 2004. The FDA subsequently returned 
nonapprovable letters for both applications, recognizing that 
efficacy for both indications had been demonstrated, but 
citing concern with regard to a theoretical risk of endome-
trial cancer and an increased risk of invasive gynecological 
procedures. With the completion of PEARL, including the 
two-year extension of the original three-year trial, a new 
application for lasofoxifene (as Fablyn) 0.5 mg/d for the treat-
ment of osteoporosis in postmenopausal women at increased 
risk of fracture (NDA 22–242) was submitted to the FDA. 
On September 8, 2008, the FDA Advisory Committee for 
Reproductive Health Drugs voted 9–3 (with one abstention) 
that there is a population of postmenopausal women with 
osteoporosis for whom the benefits of lasofoxifene likely out-
weigh the risks. The FDA has not yet issued a final ruling.
On March 24, 2009, the European Commission issued 
the first regulatory approval of lasofoxifene, as a 0.5 mg 
microfilm tablet marketed as Fablyn; it is indicated for the 
treatment of osteoporosis in postmenopausal women at 
increased risk of fracture and contraindicated for women with 
hypersensitivity to the drug of any of the excipients and those 
with a history of venous thromboembolic events, unexplained 
uterine bleeding, and women who are not postmenopausal. 
In the US, Fablyn remains under regulatory review.
If approved by the FDA, lasofoxifene will offer patients in 
the US a new option for the treatment of PMO that provides 
additional benefit over raloxifene, the only SERM that is 
currently approved for PMO in the US. Lasofoxifene should 
not be given to women with a history of thromboembolic 
events and should be used with caution, if at all, in women 
with disorders of the endometrium that increase the risk 
of uterine bleeding. Clinical experience with lasofoxifene 
in Europe is likely to provide a better understanding of its 
long-term benefits and risks.
Summary
Lasofoxifene is a SERM with proven efficacy in reducing the 
risk of vertebral and nonvertebral fractures in women with 
postmenopausal osteoporosis, reducing the risk of ER+ breast 
cancer, and relieving symptoms of vulvovaginal atrophy. It is 
well tolerated with a generally good safety profile. Lasofoxi-
fene is a promising new agent that may provide added benefit 
beyond treatment options that are currently available.
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